# A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

> **NCT01995188** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** DNIB0600A

## Key facts

- **NCT ID:** NCT01995188
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-16
- **Primary completion:** 2016-11-09
- **Final completion:** 2016-11-09
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01995188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01995188, "A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01995188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*